Temozolomide (TMZ) is a chemotherapy agent that adds mutagenic adducts to guanine, and is first-line 21 standard of care for the aggressive brain cancer glioblastoma (GBM). Methyl guanine methyl transferase 22
Introduction 44
Recent epidemiological studies show a decrease in cancer-related mortality rates attributable in part to 45 improved understanding of disease biology and better targeted therapies (Siegel et al., 2019) . However, 46 predictive models show mortality rates for the aggressive brain tumor glioblastoma (GBM) will increase 47 in 2019 (Siegel et al., 2019) . GBM is the most commonly diagnosed glioma and has an abysmal overall 48 survival rate of ~5% at 5 years (Prados et al., 2015; Wen and Kesari, 2008) . With a median survival time of 49 ~15 months, it is uniformly fatal (Nizamutdinov et al., 2018 ). Temozolomide (TMZ; Temodar) is the FDA-50 approved standard of care first line therapy for GBM in combination with surgery and radiation (Mannas 51 dementia (FTLD) (Svetoni et al., 2014) . EWSR1 has similar aggregation-prone properties (Harrison and 77 Shorter, 2017) but is more commonly studied as a fusion protein with Fli1 in Ewing's sarcoma (Grünewald 78 et al., 2015) . FET proteins also are involved in DNA repair (Izhar et al., 2015) , can bind the G4 secondary 79 structure of DNA and RNA (Takahama et al., 2011) , and play roles in isoform fate (Luo et al., 2015) . 80
Here, we exploit the known mechanism of action of TMZ, which causes a mutagenic O6-81 methylguanine adduct, to establish the role of guanine mutations in disrupting DNA secondary structures 82
in GBM and to test whether these mutations have functional impacts on TMZ-resistant GBM that can 83 be targeted pharmacologically. We found mutations in the G-rich G4s and splice sites which confer 84 increased responsiveness to a G4 stabilizing drug (TMPyP4) and a novel splicing kinase inhibitor 85 (CLK2i) in TMZ-resistant cells. We also found a differential stress response to DNA damaging agents 86 with increased nucleolar RNA:DNA hybrid R-loops, and nucleolar stress. We further identify 87 mislocalization of the G4-and RNA-binding protein EWSR1, which forms amyloid-like cytoplasmic 88 aggregates in TMZ-resistant cells that are also identified in GBM clinical specimens. This study 89 establishes a link between both altered DNA secondary structure and splicing deregulation in TMZ-90 resistant GBM, and positions cytoplasmic aggregation of EWSR1 as a potential indicator for TMZ 91 resistance and potential successful intervention with splicing modulatory or G4-targeting agents. 92
Results 93
TMZ-induced guanine mutations 94
Temozolomide (TMZ; Temodar), the FDA-approved standard of care first-line therapy for 95 glioblastoma (GBM), adds mutagenic adducts to guanine, the most prevalent being O6-methylguanine. 96
To determine the role of guanine (G) mutations in TMZ-resistance we performed whole genome 97 sequencing (WGS) on human GBM cell lines that are TMZ-sensitive cells (42MBGA), have acquired 98 resistant to TMZ through an in vitro selection against TMZ (42MBGA-TMZres) (Tiek et al., 2018) , or that 99 are intrinsically TMZ-resistant (T98G). Acquired and intrinsic TMZ-resistant cells had significantly 100 increased single nucleotide mutations relative to the TMZ-sensitive cells (Fig. 1a ). Further analysis 101 showed G>A, and C>T mutations were most enriched in TMZ-resistant cells (Fig. 1b) . These results are 102 consistent with the previously defined Signature 11 (increased C>T mutations) that is enriched in GBM 103 patient samples and has a probable association with TMZ treatment (Alexandrov et al., 2013) . 104
Two G-rich regions that are functionally and structurally important in cancer are G-quadruplexes 105 (G4s) and splice sites. G4s can readily be detected by bioinformatic analysis of WGS. To test the 106 hypothesis that G4 structures would be perturbed in TMZ-resistant cells, we used Quadron, an algorithm 107 that integrates sequence information to detect tracts of Gs and Cs with characteristic surrounding 108 sequence features of G4s (Sahakyan et al., 2017) . After all G4s were detected, we identified G4 sequences 109 unique to each cell line, and these unique G4s were then used to identify significantly enriched motifs 110 using Multiple Em for Motif Elicitation (MEME) (Bailey and Elkan, 1994) . In TMZ-sensitive 42MBGA 111 cells the top three significantly enriched G-rich sequences contain solely G's as hypothesized ( Fig. 1c ). 112
However, in the acquired resistant 42MBGA-TMZres we found enrichment of a sequence with higher 113 representation of A and T's (Sequence 3, Fig. 1c ). The T98G line, which is intrinsically resistant and 114 was not selected in culture with TMZ treatment, showed enrichment of C-and G/A-rich motifs ( Fig.  115 1c). These potential structural changes caused by mutations in G4s in the TMZ-resistant cells were then 116 validated by immunofluorescence (IF) with the G4-detecting monoclonal antibody BG4. Confirming 117 prior studies (Biffi et al., 2013) showing BG4 specifically binds DNA G4s in vivo, treatment of 42MBGA 118 cells with DNAse I abrogated specific nuclear BG4 staining ( Fig. 1d ; Supplementary Fig. 1a ). In the 119 TMZ-sensitive 42MGBA cells, discrete nuclear puncta were detected by the BG4 antibody, in addition 120 to more diffuse nucleolar staining ( Fig. 1d ; white arrows). In the acute TMZ-treated 42MGBA wild type 121 (WT) cells and both TMZ-resistant cell lines, there were no longer discrete G4 nuclear puncta, which 122 corroborated our WGS data ( Fig. 1e-g) . We then hypothesized that if disruption of G4 sequences played 123 a functional role in TMZ-resistance, a G4-stabilizing drug may be more effective as a second line 124 treatment in TMZ-resistant cells (Fig. 1h ). Treatment with TMPyP4, a G4-stabilizing drug, caused a 125 and showed the resistant cells had a significantly higher fraction of acrocentric chromosomes compared 140 to their TMZ-sensitive parental line ( Fig. 2a ). Next, we adapted the iNO score as a method of quantifying 141 nucleolar stress that accounts for both size and roundness of nucleoli (Stamatopoulou et al., 2018) . Using 142 IF detection and automated analysis of the nucleolar protein nucleolin (NCL) to determine nucleolar size 143 and circularity ( Fig. 2b) , we found significant increases in nucleolar size associated with both acute TMZ 144 treatment and intrinsic resistance (Fig. 2c ), and significant decreases in circularity, or nucleolar 145 roundness, in acute TMZ treated and both acquired and intrinsic TMZ-resistant nucleoli ( Fig. 2d ). Within 146 nucleoli, RNA polymerase I (RNAPI) transcribes ribosomal RNAs (rRNA), which can hybridize to 147 antisense ribosomal DNA (rDNA) to form rRNA:rDNA R-loops (Lindström et al., 2018) . We then used 148 the R-loop specific antibody S9.6 to visualize nucleolar R-loop changes (König et al., 2017) . The TMZ-149 sensitive 42MGBA cells showed DNA-damage induced punctated R-loop accumulation throughout the 150 nucleus (Gorthi et al., 2018) when treated with TMZ ( Fig. 2f ), compared to the nucleolar staining in 151 untreated 42MBGA-WT ( Fig. 2e ). However, TMZ-resistant cell lines showed a robust increase in 152 nucleolar R-loop accumulation, rather than nucleoplasmic puncta associated with a normal DNA damage 153 response (Gorthi et al., 2018) (Fig. 2g -i). We validated the specificity of the R-loop antibody, S9.6, by 154 treating cells with RNAse H, which digests R-loops. This treatment abrogated specific nucleolar staining 155 ( Supplementary Fig. 1d ). Overall, TMZ-resistant GBM cells exhibit an increase differential nucleolar 156 stress response with an increase in the number of acrocentric chromosomes and nucleolar size, a decrease 157 in nucleolar circularity, and differential R-loop staining patterns. 158
CLK2 inhibition preferentially targets TMZ-resistant cells 159
WGS analysis further identified a significant increase in mutations in the G-rich splice sites in TMZ-160 resistant cells ( Fig. 3a) . Splicing mutations and altered splicing patterns are characteristic of many 161 cancers, including GBM (Bejar, 2016) . To quantify changes in categories of splicing events in the TMZ-162 resistant vs sensitive cells, we performed nanopore cDNA sequencing to interrogate full length 163 transcripts. Using Full-Length Alternative Isoform analysis of RNA (FLAIR(Tang et al.)) and 164 SUPPA2 (Trincado et al., 2018) pipelines, we identified marked enrichment of skipped exons in acquired 165 and intrinsic TMZ-resistant cells (Fig. 3b ). Several splicing factor families drive exon inclusion relative 166 to exclusion events, including serine/arginine rich proteins (SRs). SR protein activity and localization 167 are dependent upon their phosphorylation status, which can be altered by DNA damage(Sakashita and 168 Endo, 2010). We also found that the DNA-damaging TMZ treatment induced a significant decrease in 169 the phosphorylation of SR proteins (pSRs) in TMZ-sensitive cells where DNA damage was measured 170
by the presence of the double-strand break marker H2AX ( Fig. 3c ). Dephosphorylation of pSRs was 171 not observed in either TMZ-resistant cell line post TMZ-treatment (Fig 3c) , suggesting altered pSR 172 function in TMZ-resistant cells. pSRs can bind both introns and exons to determine isoform fate through 173 exon inclusion or exclusion events, where SR proteins that are not hyperphosphorylated are less 174 competent to dictate isoform direction (Shepard and Hertel, 2009 ). Therefore, we sought to phenocopy the 175 3g-i). Importantly, CLK2i treatment did not cause significant changes to growth rates or cell cycle, and 186 only a modest increase in the apoptotic fraction, in the immortalized non-cancerous brain 187 oligodendrocyte cell line, MO3.13 ( Fig. 3g-i) . These data support a model in which TMZ-resistant GBM 188 cells have rewired their splicing regulatory machinery over time, as an increase in CLK2 expression was 189 not observed following acute TMZ treatment. Therefore, stably TMZ-resistant cells exhibit deregulation 190 of SR protein phosphorylation and CLK2 function, and pharmacological inhibition of CLK2 may 191 selectively target these alterations in the context of TMZ resistance. 192
193

EWSR1 mislocalization and amyloid-like cytoplasmic aggregation in TMZ-resistant cells and 194
GBM clinical specimens 195
Considering the collective deregulation of G4s, nucleoli, and splicing identified in TMZ resistant GBM 196 cells, we sought a robust, independent marker that might be an indicator for TMZ resistance and, 197 potentially, CLK2i efficacy in the future. EWSR1 is member of the FET family of proteins, which also 198 includes FUS and TAF15, where FUS is an established biomarker in many central nervous system and resistant cells ( Fig. 4a ). However, overall expression of EWSR1 did not increase with TMZ 206 resistance ( Fig. 4d ). Cytoplasmic EWSR1 aggregates were validated by a second antibody from a 207 different vendor and host species ( Supplementary Fig. 3a ). We used high resolution stimulated emission 208 depletion (STED) microscopy to better resolve the structure of these aggregates, which showed discrete 209 protein puncta within the cytoplasmic aggregates in both TMZ-resistant cell lines (Fig. 4b,c ), and 210 confirmed that the amyloid-like aggregates were specific to the cytoplasm, but not present in the nucleus 211 ( Supplementary Fig. 3b -f). 212
Cytoplasmic aggregation of EWSR1 could suggest a potential role for RNA buffering, a defining 213 feature of mis-localized RNA binding proteins in neurodegenerative diseases (Maharana et al., 2018) 214 where lower RNA concentration in the cytoplasm has been hypothesized to allow the aggregation of 215 these proteins. As EWSR1 has already been shown to relocate to the nucleoli under stressed conditions, 216
we sought to decrease the local RNA concentration and cause a stress response with low dose 217 Actinomycin D (ActD) treatment to test both the new stress response and potential role of RNA in 218 EWSR1 aggregation. Low dose ActD treatment led EWSR1 to accumulate around the nucleoli, which 219 is denoted by R-loops ( Fig. 4e ). STED imaging of these structures better resolved EWSR1, with 220 42MBGA cells showing a horseshoe shaped staining pattern that did not link to each other ( Fig. 4f ). By 221 contrast, EWSR1 formed a linked structure between the droplets in both the acquired and intrinsic TMZ-222 resistant cells ( Fig. 4g,h) . This further suggested a role for RNA buffering in EWSR1 aggregation. The 223 TMZ-resistant cells showed EWSR1 to form protein strands with decreased local RNA concentration in 224 the nucleoli, which should be studied further in the future. In addition, dual staining of EWSR1 and DNA 225
G4s showed colocalization in the TMZ-sensitive cell line that was abrogated with TMZ resistance 226 ( Supplementary Fig. 4a -c), further suggesting that the deregulation of G4s identified in TMZ -resistant 227 cells ( Fig. 1e -g) can disrupt the localization of G4-binding proteins like EWSR1. However, EWSR1 228 amyloid-like aggregates do not drive or maintain TMZ-resistance, as knockdown of EWSR1 had 229 minimal effects on cell cycle profile or specific cell death in TMZ-resistant cells ( Supplementary Fig.  230 5a-e). We further used Leptomycin B (LMB), an inhibitor of the nuclear export protein CRM1, to show 231 that EWSR1 was efficiently trafficked to and from the cytoplasm in both TMZ-sensitive and -resistant 232 lines ( Supplementary Fig 5f-h) . Ectopically expressed, YFP-tagged EWSR1 caused non-endogenous 233 ribbon-like formation of EWSR1 in the cytoplasm in the TMZ-resistant cell lines, preventing further 234 overexpression experiments ( Supplementary Fig. 5i ,j) and there were no significant changes in EWSR1 235 or CLK2 isoform profile ( Supplementary Fig. 6a-d ). Overall these studies suggest that EWSR1 is the 236 first, to our knowledge, amyloid-like aggregating protein in GBM, where RNA buffering and 237 deregulation of G4 structures may play a role in its aggregation. 238
A key limitation of studies conducted in cell culture is their dependence on ex vivo models that 239 have been in culture for decades. To determine whether EWSR1 cytoplasmic aggregates were also 240 present in clinical GBM, we stained a cohort of 15 GBM samples for EWSR1 where 9 of the 15 tumors 241 were positive for EWSR1 cytoplasmic amyloid-like aggregates ( Fig. 5a,b ). This establishes a clinically 242 relevant framework for future studies to determine the functional role of EWSR1 amyloid-like 243 aggregation in GBM. 244
Discussion 245
Since the pivotal 2005 clinical trial which changed GBM standard of care to the Stupp regimen -adjuvant 246 TMZ post-surgery and radiation -TMZ has been almost exclusively used in brain cancers, despite adding 247 only a few months to median overall survival (R et al., 2005) . Given the lack of successful FDA-approved 248 second-line treatments for GBM, we sought to identify possible dependent pathways that could be 249 targeted in TMZ-resistant GBM(De Vleeschouwer et al., 2017) . However, TMZ is rarely used in other 250 cancers, and the 400+ clinical trials to-date that have attempted to repurpose chemotherapeutic or 251 targeted agents from other cancers have failed to provide benefit in GBM (Vanderbeek et al., 2018) . We 252 therefore looked to other shown that TMZ-treated GBM has a characteristic mutational signature of C>T (Alexandrov et al., 2013) . 267
By performing whole genome sequencing (WGS), we found both C>T and G>A mutations to be 268 enriched. We focused on two key G-rich regions -G-quadruplexes (G4s) and splice sitesto assess 269 their functional roles in TMZ-resistance. We show sequence-and conformation-based changes in G4s 270 by WGS and immunofluorescence, respectively, in TMZ-sensitive vs. acute TMZ treated and TMZ-271 resistant GBM cells. We also demonstrate that the G4-targeting ligand TMPyP4 is more growth- there may be a differential DNA damage response between TMZ-sensitive and -resistant cells. 288
We further focused on G-rich splice sites and their potential contribution to aberrant regulation 289 of alternative splicing, a hallmark of many cancers (Gonçalves et al., 2017) . We showed that splicing 290 mutations are enriched in the TMZ-resistant cell lines. We then performed Oxford Nanopore Technology 291 (ONT) full-length sequencing to more globally assess whether a specific event type was enriched in the 292 TMZ-resistant cells, and this identified marked enrichment of exon skipping events. The CLK family of 293 kinases regulates the nuclear hyperphosphorylation of SR proteins, key regulators of exon fate. We 294 further showed SR proteins to be differentially phosphorylated in TMZ-sensitive versus -resistant cells 295 following TMZ treatment, found an increase in CLK2 expression in TMZ-resistant cells, and 296 demonstrated that a novel CLK2 kinase inhibitor is more growth-inhibitory in TMZ-resistant lines. 297
Targeting splicing broadly is an active area of research with clinical trials underway in SF3B1 mutant 298 cancers and neurological diseases (Seiler et al., 2018) , and our data suggest that these efforts should be 299 expanded to TMZ-resistant GBM. 300
Our data further identify EWSR1 as the first, to our knowledge, aggregating RNA-binding 301 protein in TMZ-resistant GBM. We show that EWSR1 amyloid-like aggregates form in response to acute 302 TMZ treatment and are abundant in independent models of acquired and intrinsic TMZ resistance. 303
Preliminary evidence also shows that cytoplasmic EWSR1 aggregates also are present in GBM clinical 304 samples. This aggregation phenotype is similar to DNA damaged-induced FUS aggregation observed in 305 FUS-ALS motor neurons (Naumann et al., 2018) . RNA buffering may also play a role in the aggregation 306 phenotype, as we show that inhibition of nucleolar rRNA transcription by acute Actinomycin D (ActD) 307 treatment can induce ribbon-like strands of EWSR1 around the nucleolus, though the local concentration 308 of EWSR1 would presumably be increasing as well. The last factor we explored is the ability of DNA Cells were seeded at a density of 25,000-30,000 cells onto 18mm diameter #1.5 round coverslips (VWR, 334 #101413-518) in 12-well dishes (day1). They were allowed to attach to the coverslips for a full day 335 (day2). On the following day (day3), the media was removed, cells were washed 3x with PBS, and then 336 fixed and permeabilized in 3.2% paraformaldehyde (PFA) with 0.2% Triton X-100 in PBS for 5 minutes 337 at room temperature. Three washes were performed with PBS in the 12-well plate, then coverslips were 338 inverted onto 120 μL of primary antibody in the antibody block (0.1% gelatin with 10% normal donkey 339 serum in dH2O) on strips of parafilm and incubated for two hours. Coverslips were first incubated with Cells were seeded at a density of 25,000-30,000 cells onto 18mm diameter #1.5 round coverslips (VWR, 355 #101413-518) in 12-well dishes (day1). They were allowed to attach to the coverslips for a full day 356 (day2). On the following day (day3), the media was removed, cells were washed 3x with PBS, and then 357 fixed and permeabilized in 3.2% paraformaldehyde (PFA) with 0.2% Triton X-100 in PBS for 3 minutes 358 at room temperature. 10 µL of a 1000 U of DNAse I stock was added to 500 µL of DNAse I buffer on 359 cells for 10 minutes. Cells were washed 3x with PBS and 3.2% PFA with 0.2% Triton X-100 was added 360 again for 5 minutes post-DNAse I treatment. Immunofluorescent staining was completed as stated above. 361
362
RNAse H treatment 363
Cells were seeded at a density of 25,000-30,000 cells onto 18 mm diameter #1.5 round coverslips (VWR, 364 #101413-518) in 12-well dishes (day1). They were allowed to attach to the coverslips for a full day 365 (day2). On the following day (day3), the media was removed, cells were washed 3x with PBS, and then 366 fixed and permeabilized in 3.2% paraformaldehyde (PFA) with 0.2% Triton X-100 in PBS for 3 minutes 367 at room temperature. 2 µL of a 5000 U of RNAse H stock (NEB M0297S) was added to 500 µL of 368
RNAse H buffer on cells for 5 minutes at 45 °C. Cells were washed 3x with PBS and 3.2% PFA with 369 0.2% Triton X-100 was added again for 5 minutes post-RNAse H treatment. Immunofluorescent staining 370 was completed as stated above. 
Nucleolar size and circularity detection and graphing 434
Images taken from the Leica SP8 microscope were opened in FIJI, split into the channel to be analyzed, 435 and converted from RGB to 8-bit images for analysis. In FIJI, the intensity threshold was set via Image 436 -> Adjust -> Threshold (over/under 95). Next, the image was made into a binary form (Process -> Binary 437 -> Make binary). Finally, particles that met the threshold were quantified for area and circularity via 438
Analyze -> Analyze particles. These readouts were then imported into R and graphed/analyzed using the 439 R markdown file "Raincloud_Area" in the supplemental files. 440 441
Western blot analysis 442
Cells were lysed in RIPA buffer supplemented with protease and phosphatase inhibitors (Roche, 443 #4906837001) for protein extractions and separated by polyacrylamide gel electrophoresis using 4-12% 444 gradient gels (Novex by Life Tech, #NP0321BOX) as described previously (19). They were then 445 transferred onto Nitrocellulose membranes (Invitrogen, #IB23001) with the iBlot2 (Invitrogen, 446 #IB21001) and probed with the following antibodies: EWSR1 (1:1000, abcam, ab133288), CLK2 447
(1:1000, sigma, HPA055366-100UL), phosphorylated SR proteins (clone 1H4, 1:500, Millipore, 448 #MABE50. Beta-Tubulin (1:5000, Sigma Aldrich, #T7816) and Beta-Actin (1:5000, Sigma-Aldrich, 449 #A5316) were used as loading controls. Proteins were detected with horseradish peroxidase-conjugated 450 secondary antibodies (1:5000, GE Healthcare Life Sciences, #NA931-1ML (Mouse) or #NA934-1ML 451 (Rabbit)) and enhanced chemiluminescent detection HyGLO Quick Spray Chemiluminescent (Denville 452 Scientific, #E2400) using film (Denville Scientific, #E3212). micelles for 25 minutes. This was then added dropwise to 6-wells with 1% FBS media and 100,000 470 freshly plated cells. The cells then adhered overnight, and media was changed the following morning. 471
Cells were collected 48 hours later for either cell cycle analysis or Western blot, which allowed for 72 472 hours of transfection total. 473 474
Immunohistochemistry on human GBM patient samples 475
Immunohistochemical staining of GBM was performed for EWSR1. Five-micron sections from formalin 476 fixed paraffin embedded tissues were de-paraffinized with xylenes and rehydrated through a graded 477 alcohol series. Heat induced epitope retrieval (HIER) was performed by immersing the tissue sections at 478 98 °C for 20 minutes in 10 mM citrate buffer (pH 6.0) with 0.05% Tween. Immunohistochemical staining 479 was performed using a horseradish peroxidase labeled polymer from Agilent (K4003) according to 480 manufacturer's instructions. Briefly, slides were treated with 3% hydrogen peroxide and 10% normal 481 goat serum for 10 minutes each and exposed to primary antibodies for EWSR1 (1/400, Abcam, 482 ab133288) overnight at 4 °C. Slides were exposed to the appropriate HRP labeled polymer for 30 min 483 and DAB chromagen (Dako) for 5 minutes. Slides were counterstained with Hematoxylin (Fisher, Harris 484
Modified Hematoxylin), blued in 1% ammonium hydroxide, dehydrated, and mounted with Acrymount. 485
Consecutive sections with the primary antibody omitted were used as negative controls. 486 487 RNA isolation 488 750,000 cells were seeded on day 0. The following day cells were washed 3x with PBS, trypsinized, and 489 pelleted into an Eppendorf tube. Then, 4 mL of TRIzol was added to each tube and incubated at room 490 temperature for 5 minutes. 1 mL of each sample was aliquoted into 4 separate tubes. 200 µL of 491 chloroform was added to each tube and vortexed briefly to mix. Samples incubated at room temperature 492 for 5 minutes, were briefly vortexed, and then centrifuged at 12,000g for 10 min at 4 °C. 500 µL of the 493 clear upper layer was collected from each tube and pooled into two 1 mL Eppendorf tubes where 500 494 µL of isopropanol was added and mixed thoroughly by multiple inversions. Samples were incubated for 495 15 minutes at room temperature, and then centrifuged for 15 minutes at 12,000 g at 4 °C. Supernatant 496 was then discarded, and pellet was washed with 750 µL 80% ethanol by multiple inversions. Sample 497 was centrifuged for 5 minutes at 4 °C at 12,000 g. Pellet was again washed with 80% ethanol by multiple 498 inversions and centrifuged the same way as before. The supernatant was removed and discarded, and a 499 second quick spin was done to remove any residual contaminating liquid. The RNA pellet was then air 500 dried for 10 minutes before being resuspended in 100 µL of nuclease-free water. Total RNA was 501 quantified using a NanoDrop 2000. 502 503 Nanopore sequencing 504 20 μg aliquots of total RNA were diluted in 100 μl of nuclease free water and poly-A selected using 505 were quantified and sequencing libraries were prepared using 700 ng of cDNA following the standard 514 protocol for SQK-PCS108 (1D sequencing). Sequencing was performed on the GridION platform using 515 ONT R9.4 flow cells and the standard MinKNOW protocol script (NC_48hr_sequencing_FLO-516 MIN106_SCK-PCS108). 517
Nanopore full-length sequencing analysis 518
Albacore workflow (version 2.1.3) was used for basecalling cDNA data. Using minimap2 (Li, 2018) with 519 recommended parameters (-ax splice -uf -k14), reads were aligned to the GRCh38 human genome 520 reference 2 in order to investigate possible novel isoforms. To define isoforms from the sets of cDNA 521 reads, we used FLAIR (v1.3) (Tang et al.) . Using FLAIR-correct, we corrected the aligned reads 522 providing splice site evidence from Gencode v29 (Frankish et al., 2019) annotations. The corrected and 523 filtered reads were then given to FLAIR-collapse to produce a nanopore-specific reference containing 524 high-confidence isoforms with at least 3 supporting reads. FLAIR-quantify was then used to quantify 525 Woburn, MA) using settings for a 350 bp insert size. Library quality was assessed with a BioAnalyzer 544 2100 using the High Sensitivity DNA kit (Agilent Technologies, Santa Clara, CA). The libraries were 545 quantified using the Kapa Library Quantification Kit Illumina Platforms (Kapa Biosystems, Boston, 546 MA). The denatured and diluted libraries were sequenced on a NextSeq 550 System (Illumina) using 547 v2.5 High Output 300 cycle kit with 1% PhiX to an average sequencing depth of 50X coverage. 548 549 550
Whole genome sequencing analysis 551
Raw data were first demultiplexed into 3 groups, which were 42MBGA-WT, 42MGBA-TMZres and 552 T98G, each group had two biological duplicates. All raw sequence data (fastq files) were run through 553 fastQC v0.11.7 for quality check, lower quality reads (Q < 20) were eliminated. Cutadapt v2.1 was used 554 for adapter trimming, read length less than 20 bp after trimming were filtered. Processed reads were then 555 aligned to GRCh38 reference sequence using bwa v0.7.17 paired-end mode (Li and Durbin, 2009) . 
Data availability 562
The whole genome DNA sequencing and Nanopore full-length RNA sequencing raw data generated and 563 analysed in the current study are available from the corresponding authors upon request, and will be 564 deposited to the NCBI Sequence Read Archive prior to publication. in cells with (yH2AX+) or without (yH2AX-) DNA damage; two-tailed t-test. d. Association between 613 CLK2 mRNA expression and overall survival in the REMBRANDT brain cancer data set; log-rank 614 (Mantel-Cox) test. e. Association between CLK2 expression and increasing brain tumor grade and 615 aggressiveness in the REMBRANDT dataset; one-way ANOVA. f. Western blot of CLK2 expression in 616 TMZ-sensitive, -treated, and -resistant GBM cell lines. g. FACS analysis for cell cycle profile in 617 response to 5 µM CLK2i vs. DMSO vehicle control treatment for 24 hours; three biological replicates 618
with One-way ANOVA. h. Relative cell numbers following 24 hr treatment with 5 µM CLK2i vs DMSO 619 vehicle control; three biological replicates with t-test, i. SubG1 or apoptotic DNA content in cells 620 analyzed in g; three biological replicates with t-test. * p<0.05, **p<0.001, ***p<0.0005, ****p<0.0001. 
